<DOC>
	<DOCNO>NCT03092193</DOCNO>
	<brief_summary>The family cytochrome P450 ( CYP ) important drug metabolize enzyme contribute metabolism large proportion drug human . Some CYP450 enzyme reduce alter pharmacodynamic activity many drug involve oxidative metabolism elimination many drug commonly use population . Polymorphisms CYP2C8 CYP2C9 common different population around world genetic variation allele cause decreased enzyme activity nonsteroidal anti-inflammatory drug ( NSAIDs ) celecoxib , diclofenac , ibuprofen , indomethacin , lornoxicam , meloxicam , valdecoxib , piroxicam , tenoxicam naproxen . This compromise bioavailability drug alter pharmacokinetics drug patient mutation gene exhibit increase plasma concentration value area curve ( AUC ) , addition decrease clearance drug . Associations NSAIDs gastric protector proton pump inhibitor ( PPIs ) become common nowadays , especially patient make chronic use drug . Naproxen associate esomeprazole , proton pump inhibitor ( PPI ) , launched market recently application acute pain yet elucidate . Esomeprazole suffers strong influence CYP2C19 ( hepatic drug-metabolizing enzyme degrades PPIs ) . In patient high enzyme activity CYP2C19 , drug suffer high enzymatic degradation , diminished effect . Moreover , patient low enzyme CYP2C19 activity , effect acid inhibition PPIs strong .</brief_summary>
	<brief_title>Pharmacogenetic Pharmacokinetics Naproxen Associated Naproxen-esomeprazole</brief_title>
	<detailed_description>The genotype present patient relation CYP2C8 , 2C9 2C19 could influence absorption metabolism NSAIDs without gastric protector , may differ anti-inflammatory action side effect . In proposal , 20 volunteer genotyped phenotyped haplotype cytochrome P450 . For analysis propose gene , saliva collect source genomic DNA . For molecular analysis perform polymerase chain reaction ( PCR ) assay use produce validated Applied BiosystemsÂ® . For pharmacokinetics collect saliva sample various time ingestion tablet naproxen ( 500 mg ) naproxen associate esomeprazole ( 500 + 20 mg ) , use mass spectrometry analysis drug concentration sample . The result describe 0.05 significance level .</detailed_description>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Good general health Absence infection inflammation Absence systemic disease patient systemic disease ; patient inflammation infection ; patient history gastrointestinal bleeding ulceration ; patient cardiovascular , renal hepatic disease ; patient use antidepressant drug , diuretic anticoagulant ; patient history allergy naproxen ( 500 mg ) ; patient history allergy naproxen ezomeprazole ( 500 mg 20 mg ) ; patient history allergy NSAID ; pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Naproxen</keyword>
	<keyword>Association naproxen-esomeprazole</keyword>
	<keyword>High pressure liquid chromatography</keyword>
	<keyword>Cytochrome P450</keyword>
</DOC>